Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey

Fondazione IRCCS Policlinico San Matteo di Pavia309 enrolled

Overview

Cancer patients have a well-known and higher risk of vaccine-preventable disease (VPD) than the general population. VPD can cause serious complications due to compromised immune system, malnutrition and the same oncology treatments and represent a severe financial burden with a delay in treating the underlying cancer The main purpose of this survey is to analyse the perception of cancer patients on the topic vaccines and vaccine-preventable diseases, the acceptability of vaccines and the evaluation of the determining factors associated with the choice of the patient to be vaccinated or not. This information will be used to improve the management of these issues.

Study Type

OBSERVATIONAL

Enrollment

309

Conditions

Cancer Patients Vaccine-Preventable Diseases

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. \>18 years of age; 2. Oncology patient defined as a patient with solid tumors undergoing active systemic treatment or follow-up; 3. Written informed consent Exclusion Criteria: 1. Patients with hematological tumors 2. Patients who are unable to understand informed consent document

Locations (1)

Outcomes

Primary Outcomes

assess the proportion of vaccinated subjects in our cohort of cancer patients undergoing active cancer treatment

The primary endpoint will be to assess the proportion of vaccinated subjects in the investigators cohort of cancer patients undergoing active cancer treatment (number of patients who received at least one vaccine/ total number of patients)

Time frame: 3 months

Secondary Outcomes

assess the proportion of vaccinated subjects with the anti flu vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

Time frame: 3 months

assess the proportion of vaccinated subjects with anti SARS-CoV-2 vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

Time frame: 3 months

assess the proportion of vaccinated subjects with anti pneumococccal vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

Time frame: 3 months

assess the proportion of vaccinated subjects with anti HZ vaccine in the investigators cohort of cancer patients undergoing active cancer treatment

Time frame: 3 months

assess which variables (sex, age, degree of education, marital state, commodities, type of tumor, type of oncological treatment) are associated with not willingness to receive vaccines

Time frame: 3 months